ODDITY Tech Ltd.(ODD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ODD ODDITY Tech Ltd.

Market Closed 01-30 16:00:00 EST

32.84

-0.79

-2.35%

盘后32.84

+0.000.00%

17:23 EST

High34.01	Low32.75	Vol540.51K
Open33.66	D1 Closing33.63	Amplitude3.75%
Mkt Cap1.89B	Tradable Cap1.27B	Total Shares57.44M
T/O17.85M	T/O Rate1.40%	Tradable Shares38.70M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ODD","market":"US","secType":"STK","nameCN":"ODDITY Tech Ltd.","latestPrice":32.84,"timestamp":1769806800000,"preClose":33.63,"halted":0,"volume":540508,"hourTrading":{"tag":"盘后","latestPrice":32.84,"preClose":32.84,"latestTime":"17:23 EST","volume":18016,"amount":591648.63,"timestamp":1769811794987,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.023490930716622036,"floatShares":38696732,"shares":57438900,"eps":1.791771,"marketStatus":"Market Closed","change":-0.79,"latestTime":"01-30 16:00:00 EST","open":33.66,"high":34.01,"low":32.75,"amount":17854962.90436,"amplitude":0.037467,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.791771,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770022800000},"marketStatusCode":7,"adr":0,"listingDate":1689739200000,"exchange":"NASDAQ","adjPreClose":33.63,"preHourTrading":{"tag":"盘前","latestPrice":34.27,"preClose":33.63,"latestTime":"09:20 EST","volume":20,"amount":667.9999599999999,"timestamp":1769782814859,"change":0.64,"changeRate":0.019031,"amplitude":0.028546},"postHourTrading":{"tag":"盘后","latestPrice":32.84,"preClose":32.84,"latestTime":"17:23 EST","volume":18016,"amount":591648.63,"timestamp":1769811794987,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8571051616335822,"impliedVol":0.6995,"impliedVolPercentile":0.741},"requestUrl":"/m/hq/s/ODD/tweets","defaultTab":"tweets","newsList":[{"id":"2607841680","title":"Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission","url":"https://stock-news.laohu8.com/highlight/detail?id=2607841680","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607841680?lang=en_us&edition=fundamental","pubTime":"2026-01-29 20:05","pubTimestamp":1769688300,"startTime":"0","endTime":"0","summary":"DA assigns Prescription Drug User Fee Act (PDUFA) target date of June 27, 2026Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027 LOS ALTOS, Calif., Jan.  29, 2026  (GLOBE","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/29/3228435/0/en/Unicycive-Therapeutics-Announces-FDA-Acceptance-of-Oxylanthanum-Carbonate-OLC-New-Drug-Application-NDA-Resubmission.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","ODD","LU0170899867.USD","IE00BKVL7J92.USD","BK4139","LU2237443465.HKD","LU2237443895.HKD","LU0149725797.USD","LU0882574139.USD","IE00B1BXHZ80.USD","LU0267386448.USD","LU1363072403.SGD","IE00BFXG1179.USD","LU2746668974.SGD","LU0971096721.USD","LU2237443622.USD","BK4539","IE00BZ1G4Q59.USD","LU2237443549.SGD","IE00BHPRN162.USD","CMC","LU2237443382.USD","LU2237443978.SGD","BK4183","IE0009354923.USD","LU2746668461.USD","UNCY"],"gpt_icon":0},{"id":"2606712489","title":"Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201","url":"https://stock-news.laohu8.com/highlight/detail?id=2606712489","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606712489?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:45","pubTimestamp":1769607900,"startTime":"0","endTime":"0","summary":"– Breakthrough Therapy Designation granted to NXC-201 based on positive NEXICART-2 Phase 2 interim clinical results, presented at the American Society of Hematology (ASH) 2025 annual meeting – – Final","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/28/3227633/0/en/Immix-Biopharma-Receives-U-S-FDA-Breakthrough-Therapy-Designation-for-NXC-201.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NXC","ASH","CAR","BK4230","IE0009354923.USD","BK4109","LU2463526074.USD","ODD","BK4183","BK4022"],"gpt_icon":0},{"id":"2606151727","title":"Radiopharm Theranostics Says Cash And Cash Equivalents Of Approximately $34.52m For Or The 6 Months Ended December 31, 2025 Provide Runway Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2606151727","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606151727?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:09","pubTimestamp":1769602148,"startTime":"0","endTime":"0","summary":"Program and Business Updates18F-RAD101 – Small molecule targeting fatty acid synthase radiolabeled with Fluorine-18RAD 101 is being evaluated in a single-arm U.S. Phase 2b clinical trial for the diagnostic performance of","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/01/50184651/radiopharm-theranostics-says-cash-and-cash-equivalents-of-approximately-34-52m-for-or-the-6-months-","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","BK4183","DSMC","ODD","BK4139","IE0009354923.USD","SOC","RADX"],"gpt_icon":0},{"id":"2606715341","title":"Press Release: Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2606715341","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606715341?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:00","pubTimestamp":1769601600,"startTime":"0","endTime":"0","summary":"Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI concordance in imaging study of patients with brain metastases. Interim data from additional Cohorts of the Phase 1 clinical trial of RAD 202 and RAD 204 in advanced solid tumors are expected in mid-2026. Cash and cash equivalents of approximately $34.52 million provide runway into 2027 to advance pipeline of high value radiotherapeutic programs through key clinical and regulatory milestones. RAD 101 is being evaluated in a single-arm U.S. Phase 2b clinical trial for the diagnostic performance of the molecule in 30 individuals with confirmed recurrent brain metastases from solid tumors of different origins. RAD 101 has received U.S. Food and Drug Administration  Fast Track Designation to expedite the review process and help bring the novel imaging small molecule to the over 300,000 patients diagnosed annually in the U.S. with cerebral metastases. The study is cur","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","RAD.AU","ODD","BK4213","BK7067","IE0009354923.USD","SOC","DSMC"],"gpt_icon":0},{"id":"2606550857","title":"Odd Burger Warns of Imminent Cease Trade Order Over Delayed Annual Filings","url":"https://stock-news.laohu8.com/highlight/detail?id=2606550857","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606550857?lang=en_us&edition=fundamental","pubTime":"2026-01-28 06:13","pubTimestamp":1769552002,"startTime":"0","endTime":"0","summary":"Odd Burger Corporation ( ($TSE:ODD) ) has shared an announcement. Odd Burger Corporation has warned that it expects to be hit with a failure-to-fil...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/odd-burger-warns-of-imminent-cease-trade-order-over-delayed-annual-filings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/odd-burger-warns-of-imminent-cease-trade-order-over-delayed-annual-filings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009354923.USD","BK4183","ODD"],"gpt_icon":0},{"id":"2606787367","title":"Quoin announces submission to Japanese MHLW for ODD for QRX003","url":"https://stock-news.laohu8.com/highlight/detail?id=2606787367","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606787367?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:36","pubTimestamp":1769521010,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (QNRX) announced that following a successful meeting with the Japanese MHLW that it has submitted an application for Orphan D...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-announces-submission-to-japanese-mhlw-for-odd-for-qrx003-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-announces-submission-to-japanese-mhlw-for-odd-for-qrx003-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009354923.USD","BK4183","ODD","QNRX","BK4139"],"gpt_icon":0},{"id":"2606782835","title":"Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN","url":"https://stock-news.laohu8.com/highlight/detail?id=2606782835","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606782835?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:00","pubTimestamp":1769518800,"startTime":"0","endTime":"0","summary":"Plan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 clinical trial in ATTR-CM CAMBRIDGE, Mass., Jan.  27, 2026  (GLOBE NEWSWIRE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/27/3226448/0/en/Intellia-Therapeutics-Announces-FDA-Lift-of-Clinical-Hold-on-MAGNITUDE-2-Phase-3-Clinical-Trial-in-ATTRv-PN.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","IND","IE0009354923.USD","BK4535","LU1861559042.SGD","BK4139","BK4183","LU1861558580.USD","NTLA","ATTR","ODD","BK4585","BK4588"],"gpt_icon":0},{"id":"1107142409","title":"LEADS BIOLABS-B (09887): Vilisin™ Granted Orphan Drug Designation (ODD) by European Commission for Treatment of Extrapulmonary Neuroendocrine Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1107142409","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107142409?lang=en_us&edition=fundamental","pubTime":"2026-01-22 21:10","pubTimestamp":1769087425,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that on January 22, 2026, the European Commission (EC) issued an executive decision dated January 9, 2026, granting Orphan Drug Designation (ODD) to the PD-L1/4-1BB...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","09887","HK0000500386.USD","ODD","BK4183","HK0000252160.HKD","BK1161","IE0009354923.USD"],"gpt_icon":0},{"id":"2604311804","title":"Dyne announces MHLW in Japan granted ODD for zeleciment basivarsen","url":"https://stock-news.laohu8.com/highlight/detail?id=2604311804","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604311804?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:36","pubTimestamp":1768912563,"startTime":"0","endTime":"0","summary":"Dyne Therapeutics (DYN) announced that the Ministry of Health, Labour and Welfare, MHLW, in Japan has granted Orphan Drug designation, ODD, for zel...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dyne-announces-mhlw-in-japan-granted-odd-for-zeleciment-basivarsen-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dyne-announces-mhlw-in-japan-granted-odd-for-zeleciment-basivarsen-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DYN","BK4183","BK4139","BK4585","IE0009354923.USD","BK4588","BK4505","ODD"],"gpt_icon":0},{"id":"2604538401","title":"Insider-Favored Growth Stocks To Consider In January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2604538401","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604538401?lang=en_us&edition=fundamental","pubTime":"2026-01-20 01:06","pubTimestamp":1768842365,"startTime":"0","endTime":"0","summary":"As the U.S. stock market grapples with rising Treasury yields and a cautious Federal Reserve outlook, investors are keenly observing growth companies where insiders have significant ownership stakes. In such uncertain times, stocks with high insider ownership can signal confidence in the company's long-term prospects, making them an intriguing consideration for those navigating today's complex market landscape.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-tpc/tutor-perini/news/insider-favored-growth-stocks-to-consider-in-january-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-tpc/tutor-perini/news/insider-favored-growth-stocks-to-consider-in-january-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2065171311.SGD","CWBC","ODD","BK4096","BK4108","LU0719512351.SGD","BK4213","LU2065170008.USD","BK4600","LU1861220033.SGD","BK4532","LU2931357623.SGD","BK4091","LU1861215975.USD","PROP","CORT","IE0009354923.USD","BK4211","BK4555","BK4585","LU2290526834.HKD","LU0053671581.USD","BK4129","BK4141","BK4558","LU0082616367.USD","GBFH","LU2360107168.USD","BK4170","STUB","BK4007","BK7136","BK4192","LU1559883803.SGD","LU2065169927.USD","BK4023","BK4595","BTDR","LU2065171402.SGD","LU2089985449.USD","BK4603","SMCI","LU0274383776.USD","BK4183","LU0566484027.USD","NIU","SES","BK4588","BK4543","TPC"],"gpt_icon":1},{"id":"2604450789","title":"Assessing Oddity Tech (ODD) Valuation After Analyst Praise And METHODIQ Skincare Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2604450789","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604450789?lang=en_us&edition=fundamental","pubTime":"2026-01-17 12:29","pubTimestamp":1768624166,"startTime":"0","endTime":"0","summary":"Oddity Tech (NasdaqGM:ODD) is back in focus after an influential analyst highlighted its recent skincare launch, METHODIQ, along with consistent revenue growth and EBITDA margins near 20%, which has helped lift investor interest in the stock.\nSee our latest analysis for Oddity Tech.\nAt a share price of $35.34, Oddity Tech has seen a 4.56% 1 day share price return, but weaker 30 day and 90 day share price returns of 16.34% and 30.50%, with a 1 year total shareholder return of 19.39%. This...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/household/nasdaq-odd/oddity-tech/news/assessing-oddity-tech-odd-valuation-after-analyst-praise-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/household/nasdaq-odd/oddity-tech/news/assessing-oddity-tech-odd-valuation-after-analyst-praise-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4543","ODD","BK4585","BK4587","BK4588","BK4601","BK4023","BK4528","IE0009354923.USD","BK4551","ETH","BK4183","BK6100","AI","NPL.SI"],"gpt_icon":0},{"id":"2603934843","title":"Odd Burger Delays Annual Filings After Financing Default Triggers Liquidity Crunch","url":"https://stock-news.laohu8.com/highlight/detail?id=2603934843","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603934843?lang=en_us&edition=fundamental","pubTime":"2026-01-16 07:38","pubTimestamp":1768520309,"startTime":"0","endTime":"0","summary":"Odd Burger Corporation ( ($TSE:ODD) ) has issued an announcement. Odd Burger Corporation has warned that it will miss the January 28, 2026 deadline...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/odd-burger-delays-annual-filings-after-financing-default-triggers-liquidity-crunch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/odd-burger-delays-annual-filings-after-financing-default-triggers-liquidity-crunch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ODD","IE0009354923.USD","BK4183"],"gpt_icon":0},{"id":"2603524582","title":"ODDITY Tech Secures Expanded $350 Million Credit Facilities to Fund Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2603524582","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603524582?lang=en_us&edition=fundamental","pubTime":"2026-01-13 06:47","pubTimestamp":1768258077,"startTime":"0","endTime":"0","summary":"The latest update is out from ODDITY Tech Ltd. Class A ( ($ODD) ). On January 12, 2026, ODDITY Tech Ltd. disclosed that it has amended its existing...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oddity-tech-secures-expanded-350-million-credit-facilities-to-fund-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oddity-tech-secures-expanded-350-million-credit-facilities-to-fund-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ODD","IE0009354923.USD","BK4183"],"gpt_icon":0},{"id":"2603216885","title":"Oddity Tech Ltd: Co Has Entered Into Amendments to Existing Agreements With Syndicate of Banks to Secure Credit Facilities for Total of $350 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2603216885","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603216885?lang=en_us&edition=fundamental","pubTime":"2026-01-13 06:21","pubTimestamp":1768256515,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD1S1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ODD","BK4183","IE0009354923.USD"],"gpt_icon":0},{"id":"2603252156","title":"Oddity Tech Secures $350 Million Credit Facility to Boost Growth and Flexibility","url":"https://stock-news.laohu8.com/highlight/detail?id=2603252156","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603252156?lang=en_us&edition=fundamental","pubTime":"2026-01-13 06:20","pubTimestamp":1768256434,"startTime":"0","endTime":"0","summary":"Oddity Tech Ltd. has secured amendments to its existing credit agreements with a syndicate of banks, increasing its available credit facilities from $200 million to $350 million. The new agreements, effective January 15, 2026, will provide the company with undrawn credit lines available for drawdown over three years, through January 14, 2029. Borrowings will accrue interest at SOFR plus 2.7% for term loans maturing in 2031, and a 0.3% commitment fee will apply to unused amounts. The facilities are intended to enhance Oddity Tech’s financial flexibility for growth initiatives, acquisitions, share buybacks, and general corporate purposes, and are subject to customary covenants, including a net debt-to-EBITDA ratio not exceeding 4x. The agreements are guaranteed by certain company subsidiaries and benefit from a negative pledge.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL7TdQkq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","ODD","IE0009354923.USD"],"gpt_icon":0},{"id":"2602548878","title":"Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2602548878","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602548878?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222800,"startTime":"0","endTime":"0","summary":"Company to also participate in Fireside Chat at Lytham Partners 2026 Investor Healthcare Summit on Thursday, January 15, 2026SAN FRANCISCO, Jan.  12, 2026  (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, I","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/12/3216838/0/en/Cadrenal-Therapeutics-Highlights-High-Incidence-of-Thrombotic-Complications-in-Heparin-Induced-Thrombocytopenia-HIT-at-the-J-P-Morgan-Healthcare-Conference-and-VLX-1005-as-a-Potent.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","LU0314104364.USD","LU1732800096.USD","LU1244550494.USD","LU0528227936.USD","LU0225283273.USD","LU1548497426.USD","LU0912757837.SGD","LU0267386448.USD","LU0882574139.USD","BK4581","IE00BKVL7J92.USD","LABU","BK4109","LU1791710582.SGD","HIT","LU2357305700.SGD","LU1732799900.SGD","LENZ","LU2463526074.USD","LU1989772923.USD","BK4504","LU0795875169.SGD","LU2271345857.HKD","LU0106831901.USD","LU1162221912.USD","BK4139","LU0006306889.USD","LU0795875086.SGD","LU2111349929.HKD","LU0234570918.USD","BK4588","BK4007","LU0557290698.USD","LU0320765646.SGD","LU1668664300.SGD","BK4183","XLV","LU0029874061.USD","BK4137","LU1791710400.SGD","LU2133065610.SGD","LU2089283258.USD","LU1720051017.SGD","BK4539","HCSG","LU0128526141.USD","LU1989772840.SGD","ASH","XBI"],"gpt_icon":0},{"id":"2601260393","title":"Is It Time To Reassess Oddity Tech (ODD) After Recent Share Price Weakness?","url":"https://stock-news.laohu8.com/highlight/detail?id=2601260393","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601260393?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:40","pubTimestamp":1767883258,"startTime":"0","endTime":"0","summary":"If you are wondering whether Oddity Tech at around US$38 is attractively priced or not, this article walks through what the numbers say about its current valuation.\nThe share price has recently been under pressure, with returns of a 5.4% decline over the last 7 days, an 11.6% decline over 30 days, and a 12.4% decline over the past year. This can change how investors think about both risk and opportunity.\nRecent coverage of Oddity Tech has focused on how the business is positioning itself...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/household/nasdaq-odd/oddity-tech/news/is-it-time-to-reassess-oddity-tech-odd-after-recent-share-pr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/household/nasdaq-odd/oddity-tech/news/is-it-time-to-reassess-oddity-tech-odd-after-recent-share-pr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4183","DCF","IE0009354923.USD","ODD"],"gpt_icon":0},{"id":"2601988133","title":"ODDITY Tech Is Maintained at Overweight by Keybanc","url":"https://stock-news.laohu8.com/highlight/detail?id=2601988133","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601988133?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:29","pubTimestamp":1767882540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ODD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2026 09:29 ET (14:29 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD"],"gpt_icon":0},{"id":"2601637023","title":"KeyBanc Reaffirms Their Buy Rating on ODDITY Tech Ltd. Class A (ODD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2601637023","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601637023?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:16","pubTimestamp":1767870990,"startTime":"0","endTime":"0","summary":"In a report released today, Scott Schoenhaus from KeyBanc maintained a Buy rating on ODDITY Tech Ltd. Class A, with a price target of $50.00. Accor...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/keybanc-reaffirms-their-buy-rating-on-oddity-tech-ltd-class-a-odd-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/keybanc-reaffirms-their-buy-rating-on-oddity-tech-ltd-class-a-odd-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ODD"],"gpt_icon":0},{"id":"2601389221","title":"Oddity Tech Ltd. Chief Science Officer Departs","url":"https://stock-news.laohu8.com/highlight/detail?id=2601389221","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601389221?lang=en_us&edition=fundamental","pubTime":"2026-01-08 05:26","pubTimestamp":1767821203,"startTime":"0","endTime":"0","summary":"Oddity Tech Ltd. announced that Dr. Ido Bachelet is no longer employed with the company. His responsibilities as Chief Science Officer of ODDITY LABS have been taken over by other members of the leadership team. The company stated that this change will not affect its financial outlook or ongoing projects.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oddity Tech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 07, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL3h5fcF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","IE0009354923.USD","ODD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://oddity.com","stockEarnings":[{"period":"1week","weight":-0.0728},{"period":"1month","weight":-0.1827},{"period":"3month","weight":-0.2743},{"period":"6month","weight":-0.542},{"period":"1year","weight":-0.2993},{"period":"ytd","weight":-0.1827}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0147},{"period":"3month","weight":0.0145},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1437},{"period":"ytd","weight":0.0147}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Oddity Tech Ltd. operates as a consumer tech company that builds and scales digital-first brands to disrupt beauty and wellness industries. The company serves consumers worldwide through its AI-driven online platform, deploying data science to identify consumer needs, and developing solutions in the form of beauty and wellness products. It owns IL MAKIAGE and SpoiledChild brands. The company was incorporated in 2013 and is headquartered in Tel Aviv, Israel with additional office in New York, New York.","exchange":"NASDAQ","name":"ODDITY Tech Ltd.","nameEN":"ODDITY Tech Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ODDITY Tech Ltd.(ODD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ODDITY Tech Ltd.(ODD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ODDITY Tech Ltd.,ODD,ODDITY Tech Ltd.股票,ODDITY Tech Ltd.股票老虎,ODDITY Tech Ltd.股票老虎国际,ODDITY Tech Ltd.行情,ODDITY Tech Ltd.股票行情,ODDITY Tech Ltd.股价,ODDITY Tech Ltd.股市,ODDITY Tech Ltd.股票价格,ODDITY Tech Ltd.股票交易,ODDITY Tech Ltd.股票购买,ODDITY Tech Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ODDITY Tech Ltd.(ODD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ODDITY Tech Ltd.(ODD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}